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Figure: Hsu, Lander, Zhang: Development and applications of CRISPR-Cas9 for Genome 
Engineering:Cell157, June5, 2014
CRISPR loci and Cas nucleases nomenclature
CRISPR: Clustered Regulatory Interspaced Palindromic repeats
Loci in %40 of bacteria and %90 of archea
Cas9: CRISPR associated protein9 
A nuclease, an enzyme specialized for cutting DNA
gRNA: a construct/chimera of CRISPR RNA(crRNA) 
and trans-activating CRISPR RNA(tracrRNA)
PAM: proto spacer adjacent with sequence NGG(any, 
guanine, guanine) specific to Streptococcus pyogenes
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Action Of CRISPR in bacteria
The CRISPR immune system works to protect bacteria from 
repeated viral attack via three basic steps:
(1) Adaptation
(2) Production of crRNA
(3) Targeting
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Figures: Annu.Rev.Genet.2011.45:273-97 and Horvath: science (2010) vol.327;167-170: CRISPR/Cas , the 
immune system of Bacteria and Archaea
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The gRNA forms a 
complex with Cas directs 
the enzyme to cleave the 
target DNA to switch the 
gRNA binds through 
complementarysequences
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Endogenous DNA repair mechanisms
Figure : Hsu ,Lander ,Zhang : development and applications of CRISPR-Cas9 for Genome 
Engineering: cell157,June 5,2014 22
First: we have to designing crRNA
How ?  
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Second: Cas9        
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Transmission methods:
 Nucleofectin
 Lipofection
 Electroporation
 CPP
 Viral vectors
 Nano particle
 Microfluidic membrane
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Selected in silico prediction  assays
Selected in silico predidiction assays   Resources
Cas-OFFinder http://WWW.rgenome .net/cas-offinder
CRISPR Design Tool                                    http://crisp.mit.edu/
CasFinder http://arep.med.harvard.edu/CasFinder
E-CRISP http://WWW.e-crisp.org/E-CRISP/
Breaking-cas http://bioinfogp.cnb.csic.ec/tools/breakingcas/
CRISPOR http://crispor.tefor.net
CHOPCHOP http://chopchop.cbu.uib.no
44
In vitro genome-wide assays
Selected in vitro genome-wide assays Description
Digenome-Seq
Purified genomic DNA is digested with a 
nuclease and subjected to whole genome 
sequencing .Off targets are computationally 
identified
CIRCLE-Seq
Purified genomic DNA is sheared  and 
circularized, and residual linear DNA us 
degraded. The Cas9 nuclease is used to linearize 
circular DNA containing  a Cas9 cleavage site, 
and the cleaved ends are PCR-amplified and 
sequenced to identify off-targets.
SITE-Seq Purified genomic DNA is cleaved using Cas9, 
and Cas9 cleavage sites are biochemically tagged 
and   enriched . Next-gene sequencing and 
bioinformatics analysis is then used to identify 
off-targets cleavage sites.
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Cell-based genome-wide assays
Selected cell-based genome-wide assays Description
GUIDE-Seq
Double-stranded breaks created by the 
Cas9 nuclease are tagged using small 
double-stranded oligonucleotides, PCR 
amplified, and sequenced to map the 
double-stranded breaks
LAM-HTGTS Chromosomal translocations of off-
target and on-target breaks are PCR 
amplified and analyzed by next-gene 
sequencing
BLISS Double-stranded breaks are 
biochemically labeled, and their 
downstream sequences are amplified 
using in vitro transcription and analyzed 
using next-gene sequencing.
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Challenges for CRISPR
 Off target
 Mosaic mutations
 Low rate of homologous recombination
 Low efficiency of in vivo delivery
 Immunogenicity of CRISPR/Cas9 and delivery vehicles
 Bio-distribution
 Fitness of edited cells 51
Future applications in biomedicine and biotechnology 
Source: Jennifer A. Doudna and Emmanuele Charpentier, The new frontier of genome 
engineering with CRISPR-Cas9 , ScienceMag2014, VOL 346 ISSUE 6213 51
Software and Databases
Figures: Software data bases and Publications 52
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The potential of CRISPR-Cas9 for treating genetic disorders
Disease   Target gene Transmission method Target cell Efficiency 
level(%)
Beta-thalasemia Gene deletion HHB
Electroporation
Human ipsc
cells,human
zygote
17.6
14.3
Cystic fibrosis Gene deletion CFTR
Lipofection
Human organoid
intestine cells …..
HIV-1
Inactivation DNA of 
provirus
Electroporation
Human ipsc
cells, JL.at10.6 
cells
100
30
DMD Exon deletion in 
distrophin gene
Electroporation Human ipsc cells 50
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Disease Target gene Transmission
method
Target cell Efficiency 
level(%)
Tyrosinemia(type 1) Point mutation in 
FAH gene
Hydrodynamic 
injection
Human ipsc cells 0.4
AAT Defficiency Point mutation in 
SERPINA1
Electroporation Human ipsc cells 18.8
Polycythemia-vera Point mutation in 
JAK2
Electroporation Human ipsc cells 9.15
Cataract Deletion of crygc Electroporation Spermatogonic & 
stemcells of the mouse
29.7
LDL-C Deletion of pcsk9 AAV Mouse liver
in vitro cells
50
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Is a fatal X-linked recessive neuromuscular disease prevalent 
in 1 in 3500 to 5000 males world wide
Progressive muscle weakness
Defects in muscle proteins
Death of muscle tissue
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More symptoms of DMD
Muscle weakness
Delayed developmental milestones
Difficulty rising (Gower’s sign)
Difficulty walking/running
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DMD-mutation targeting strategies by CRISPR-Cas9
59
Ex-vivo gene therapy with 
CRISPR-Cas9 in autologous
stem cells.
Fibroblasts are derived from a 
DMD patient affected by an out-
of-frame mutation. Subsequently 
, fibroblasts are reprogrammed 
into ipscs. CRISPR-Cas9 
corrects the ORF of ipscs by 
using an multi-exon deletion 
approach. Corrected ipscs are 
differentiated into muscle stem 
cells and transplanted back into 
the patient.
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THE KAVLI PRIZE
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He Jiankui says he is proud 
of the work that has led to 
the birth of genetically 
changed twins Nana and 
Lulu.
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